Lancet Respiratory Medicine,The
Công bố khoa học tiêu biểu
* Dữ liệu chỉ mang tính chất tham khảo
Sắp xếp:
CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a Position Paper from the Fleischner society
Lancet Respiratory Medicine,The - Tập 3 Số 6 - Trang 483-496 - 2015
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study
Lancet Respiratory Medicine,The - Tập 10 - Trang 1019-1028 - 2022
Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study
Lancet Respiratory Medicine,The - Tập 6 - Trang 545-553 - 2018
Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial
Lancet Respiratory Medicine,The - Tập 2 - Trang 361-368 - 2014
Pulmonary alveolar proteinosis in adults: pathophysiology and clinical approach
Lancet Respiratory Medicine,The - Tập 6 - Trang 554-565 - 2018
Fast multiplex bacterial PCR of bronchoalveolar lavage for antibiotic stewardship in hospitalised patients with pneumonia at risk of Gram-negative bacterial infection (Flagship II): a multicentre, randomised controlled trial
Lancet Respiratory Medicine,The - Tập 10 - Trang 877-887 - 2022
Effect of rare variants in ADRB2 on risk of severe exacerbations and symptom control during longacting β agonist treatment in a multiethnic asthma population: a genetic study
Lancet Respiratory Medicine,The - Tập 2 - Trang 204-213 - 2014
Safety of the fourth COVID-19 BNT162b2 mRNA (second booster) vaccine: a prospective and retrospective cohort study
Lancet Respiratory Medicine,The - Tập 11 - Trang 139-150 - 2023
Predicting the future risk of lung cancer: development, and internal and external validation of the CanPredict (lung) model in 19·67 million people and evaluation of model performance against seven other risk prediction models
Lancet Respiratory Medicine,The - Tập 11 - Trang 685-697 - 2023
Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial
Lancet Respiratory Medicine,The - Tập 9 - Trang 585-592 - 2021
Tổng số: 435
- 1
- 2
- 3
- 4
- 5
- 6
- 10